Literature DB >> 28321235

Aortic valve disease in the older adult.

Neal Bhatia1, Sukhdeep S Basra2, Adam H Skolnick3, Nanette K Wenger1.   

Abstract

Entities:  

Keywords:  Aortic stenosis; The elderly; Valve disease

Year:  2016        PMID: 28321235      PMCID: PMC5351823          DOI: 10.11909/j.issn.1671-5411.2016.12.004

Source DB:  PubMed          Journal:  J Geriatr Cardiol        ISSN: 1671-5411            Impact factor:   3.327


× No keyword cloud information.

Introduction

As the population continues to age, aortic stenosis remains as the most prevalent valvular disease in Western countries.[1] The number of elderly patients with aortic stenosis continues to pose both a diagnostic and therapeutic challenge. Despite new advances such as transcatheter aortic valvular replacement (TAVR), there is still much patient-provider decision making that needs to take place given the comorbidities and complex goals of care in an elderly patient population. The increased longevity due to advances in health care has resulted in an increase in diagnosis of aortic stenosis. While the prevalence is low in patients < 60 years of age, it increases to approximately 10% in patients > 80 years of age.[2] The severity of aortic stenosis increases with age, with one in eight people older than age 75 showing moderate to severe aortic stenosis.[3] This represents a significant health care burden that is projected to increase as the population progressively ages. Age related, or degenerative valvular heart disease, represents the most common etiology of aortic stenosis in the elderly population. Degenerative aortic valve disease affects over 25% of all patients over the age of 65. Most patients have only mild thickening and normal valve function, called aortic sclerosis. However, 2%–5% of these patients have significant aortic stenosis with obstruction of left ventricular outflow.[4] Clinical risk factors for degenerative aortic valve stenosis mirror those associated with coronary atherosclerosis. Traditional cardiovascular risk factors such as age, male gender, smoking, elevated LDL cholesterol, hypertension, and metabolic syndrome have been associated with development and progression of aortic stenosis.[5],[6] Elderly patients with aortic stenosis typically have concomitant coronary or peripheral vascular disease. Risk factors associated with disease initiation may differ from those that promote disease progression, but disease progresses more rapidly at elderly age. Aortic valve disease constitutes a chronic, progressive disease over time. Mild fibro calcific leaflet changes progress to active bone formation on the aortic valve apparatus, causing significant obstruction to left ventricular outflow. Otto, et al.[7] noted initial aortic lesions containing disorganized collagen fibers, chronic inflammatory cells, proteins of extracellular bone matrix and bone minerals, suggesting that this is a chronic inflammatory process. Hemodynamic stress initiates endothelial activity, contributing to aortic valvular damage. Increased calcification of the valve cusps causes increased valvular stiffness and narrowing. Over time, an increased aortic gradient causes a pressure overload resulting in left ventricular (LV) wall thickening and hypertrophy. Sustained hypertrophy and pressure over time contribute to LV diastolic dysfunction and left ventricular strain, leading to left ventricular failure.[7] Given the similarity of both coronary atherosclerosis and aortic stenosis it was hoped that prevention and treatment with cardiovascular drugs would prevent progression of aortic stenosis. Treatment with medications such as beta blockers or statins have not proved of benefit in reducing or halting progression of aortic stenosis. The use of statins to reduce aortic calcification in hope that it could prevent progression of aortic stenosis has been disappointing. While initial studies showed some benefit,[8]–[10] a recent meta-analysis showed that statins had no effect on aortic valve structure, function, calcification, and clinical outcomes.[11] Similarly, bisphosphonates had been posited to ameliorate aortic stenosis progression but have not been proven helpful in prospective studies. There is some promise for other medications such as angiotensin converting enzyme inhibitors (ACEI) — some studies have shown changes in hemodynamics due to improved left ventricular unloading, although this requires further investigation.[10] When evaluating the elderly patient for aortic stenosis, clinicians often have a myopic focus on the valve as the main cause of the patients' complaints. The presence of comorbidities, which are often severe, should be taken into account. Medical comorbidities can affect the outcome of procedures and full evaluation is warranted. In elderly patients with significant lung disease such as pulmonary hypertension or chronic obstructive pulmonary disease, it can be difficult to discern whether symptoms are due to a cardiovascular or lung pathology. Replacement of the valve might not improve clinical symptoms or outcomes. In patients who underwent TAVR, 60% had significant lung disease, with up to 30% having oxygen dependence.[12] In patients undergoing aortic valve replacement, significant lung disease has been associated with an increase in morbidity and mortality.[13] Another small cohort study found a prevalence of 77% of significant sleep-related breathing disorders.[14] Chronic kidney disease, liver disease, and anemia have been independently associated with increased mortality after aortic valve replacement.[15]

Diagnosis

In evaluating elderly patients with aortic stenosis, it is important to elicit a comprehensive and meticulous history. The three cardinal symptoms of aortic stenosis that prompt urgent valve replacement include angina, syncope, and heart failure symptoms (including orthopnea, edema, and paroxysmal nocturnal dyspnea). In the elderly population, it can be difficult to elicit these symptoms as many patients have significantly decreased mobility or might not complain of these symptoms. It is integral to involve family members or caretakers who might notice a change in activity, appetite, or overall health. While carefully supervised exercise testing can help evaluate those who are truly asymptomatic, other procedures such as a gait evaluation can help the clinician determine if hemodynamically significant aortic stenosis is the culprit. While patients might be categorized asymptomatic due to lack of functional impairment, a very high event rate can be expected with echocardiographic evidence of significant aortic stenosis and warrants clinical follow up.[16] It is important to determine whether symptoms are related to aortic stenosis. Patients with limited mobility, deconditioning, or oxygen dependent lung disease may have dyspnea unrelated to their valvular pathology such that treatment with valve replacement would not produce benefit. The physical examination can further provide clues on the severity of the aortic stenosis and burden on the cardiovascular system. Presence of a delayed carotid upstroke, a sustained point of maximal impulse due to LV hypertrophy, and a harsh, late peaking systolic murmur best heard in the right or left upper sternal border are compatible with severe aortic stenosis. However, vascular stiffness may mask the delayed aortic upstroke and dorsal kyphosis may lessen murmur intensity. In the elderly, the murmur intensity may even decrease as stroke volume declines. In severe aortic stenosis, the aortic component of S2 is either soft or absent. While the physical examination can point the clinician toward aortic stenosis, further evaluation with echocardiography is warranted. Transthoracic echocardiography (TTE) remains the gold standard for evaluating aortic stenosis. Evaluation of LV wall thickness, systolic function, and aortic valve morphology can be assessed with two dimensional imaging. Doppler echocardiography provides hemodynamic measurement, severity of valvular stenosis and regurgitation, and pulmonary pressures.[17] Aortic stenosis is considered severe when the peak velocity is greater than 4 m/s, peak gradient is greater than 64 mmHg, mean gradient is greater than 40 mmHg, or aortic valve area is less than 1.0 cm2.[18] Further testing with submaximal stress testing can be useful in evaluation if the patient is asymptomatic.[18] Clinicians should not depend solely on the echocardiogram for clinical decision-making. It is imperative that the clinician is able to connect the history, physical findings, and imaging results. This will allow to the clinician to be aware of any discrepancies which might warrant further investigation. Other imaging modalities for further evaluation include transesophageal echocardiogram, computed tomography, cardiac catheterization and cardiac magnetic resonance. Once the decision is made for aortic valve replacement, coronary artery anatomy must be assessed re need for concomitant coronary revascularization.

Treatment

Aortic stenosis has high morbidity and mortality after the occurrence of symptoms, where the two year mortality risk is higher than 50%.[16] Aortic valve replacement with either open heart surgery or TAVR are the only treatment modalities that reduce morbidity and mortality with significant aortic stenosis. Prior to the advent of TAVR, over one third of patients were unsuitable to undergo valve replacement due to age-related comorbidities.[19] TAVR has emerged as an alternative in those who cannot undergo or who are high risk for surgical valve replacement.[12],[20] The AHA/ACC valvular guidelines recommend valve replacement in symptomatic patients with evidence of left ventricular dysfunction, in the presence of severe aortic stenosis.[18] More importantly, they recommend a multidisciplinary heart valve team approach when deciding on individualized treatment. This is paramount in patients who are elderly and have nontraditional risk factors that are not seen in younger cohorts. When evaluating risk, it is important to evaluate frailty, disability, mobility, cognitive impairment, malnutrition, and fall risk. Equally important is shared clinician-patient decision-making. Frailty is defined as a state of vulnerability, a syndrome characterized by decreased reserve and diminished resistance to stressors.[21] This evaluation provides better insight into the “physiological age” of the patient.[22] Increasing evidence shows an increase in cardiovascular mortality in patients with frailty, independent of other comorbidities.[23],[24] Traditionally, surgical risk of aortic valve replacement is estimated using two scores: the Society of Thoracic Surgery (STS)[25] and the European System for Cardiac Operative Risk Evaluation.[26] Unfortunately, neither of these scores take into consideration frailty, cognitive disorders, multimorbidity, or social support, which are of importance in this population undergoing valvular replacement. The evaluation of gait speed and comprehensive geriatric assessment is advocated for all older, complex patients with symptomatic aortic stenosis since it can predict further outcomes beyond the traditional scoring systems.[22] Other factors that should be considered when deciding for valve replacement include high STS score, impaired left ventricular systolic function, low valve gradients, reduced stroke volume, severe myocardial fibrosis, and severe pulmonary hypertension.[27] Despite the significant comorbidities of the elderly, the outcomes for aortic valve replacement have been improving. Vasques, et al.[28] reviewed 48 studies with patients over the age of 80 and showed an improvement of morbidity and mortality from 7.5% to 5.8% over the past twenty years. In the era of TAVR, the postoperative mortality in octogenarians after 2000 was between 2.4% and 6.8%.[29] Postoperative complications of concern are stroke, paravalvular leaks, and vascular complications (vascular dissection perforation, hematoma, bleeding). Randomized trials have shown no significant differences in mortality between surgical valve replacement (SAVR) vs. TAVR in patients who are high risk. Patients undergoing SAVR have a higher risk of bleeding, kidney injury, and atrial fibrillation while those who undergo TAVR have higher vascular complication, paravalvular leak, and permanent pacemaker insertion.[12] Recent studies of TAVR in the elderly have shown that despite significant comorbidities, frailty, and high STS scores, they have an acceptable short and long term survival benefit along with improvements in function and quality of life.[30] Elderly patients and their families must be queried and presented both the risks and benefits of SAVR and TAVR prior to allow for informed decision-making. An overlooked aspect of the decision to pursue valve replacement involves discussing expectations with patients and setting realistic goals for enhancements in quality of life and reduction of disease burden. With the help of geriatricians and primary care physicians, it appears possible to better identify frail patients with diminished physiological reserve versus patients with the potential to recover after intervention.[31] Establishing a framework to align patient goals and outcomes can aid in decisions regarding potential treatment options. If a patient is thought to have prohibitively high risk where intervention would be futile, end-of-life planning should be pursued. In all patients it is essential to delineate goals of care in advance.

Follow up

After valve replacement, careful monitoring and management of comorbidities is crucial. Elderly patients are at higher risk of bleeding, renal failure, arrhythmias, heart block, and cognitive decline. Patient who have severe, symptomatic aortic stenosis have significant decline in preoperative functional capacity, and often severe malnutrition, leaving patients at higher risk postoperatively. Jagielak, et al.[32] showed that among elderly patients undergoing aortic valve replacement, 39.4% were diagnosed preoperatively as malnourished. Hospitalization is invariably associated with functional decline and perioperative delirium may result in cognitive decline. Mobility and rehabilitation after valve replacement remains important, with some promise seen in cardiopulmonary rehabilitation in elderly patients going TAVR.[33] Close follow up with the primary care physician or geriatrician is warranted to evaluate for long term complications or changes in coexisting medical conditions.
  31 in total

Review 1.  The effect of statins on valve function and calcification in aortic stenosis: A meta-analysis.

Authors:  Ying Zhao; Rachel Nicoll; Yi Hua He; Michael Y Henein
Journal:  Atherosclerosis       Date:  2016-01-19       Impact factor: 5.162

2.  Asymptomatic Severe Aortic Stenosis in the Elderly.

Authors:  Robert Zilberszac; Harald Gabriel; Michael Schemper; Günther Laufer; Gerald Maurer; Raphael Rosenhek
Journal:  JACC Cardiovasc Imaging       Date:  2016-09-14

3.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

Authors:  Luis M Moura; Sandra F Ramos; José L Zamorano; Isabel M Barros; Luis F Azevedo; Francisco Rocha-Gonçalves; Nalini M Rajamannan
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

4.  Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry.

Authors:  Neil E Moat; Peter Ludman; Mark A de Belder; Ben Bridgewater; Andrew D Cunningham; Christopher P Young; Martyn Thomas; Jan Kovac; Tom Spyt; Philip A MacCarthy; Olaf Wendler; David Hildick-Smith; Simon W Davies; Uday Trivedi; Daniel J Blackman; Richard D Levy; Stephen J D Brecker; Andreas Baumbach; Tim Daniel; Huon Gray; Michael J Mullen
Journal:  J Am Coll Cardiol       Date:  2011-10-20       Impact factor: 24.094

5.  Transcatheter versus surgical aortic-valve replacement in high-risk patients.

Authors:  Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 6.  Quantitative hemodynamics by Doppler echocardiography: a noninvasive alternative to cardiac catheterization.

Authors:  R A Nishimura; A J Tajik
Journal:  Prog Cardiovasc Dis       Date:  1994 Jan-Feb       Impact factor: 8.194

7.  Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis.

Authors:  Spencer J Melby; Marc R Moon; Brian R Lindman; Marci S Bailey; Laureen L Hill; Ralph J Damiano
Journal:  J Thorac Cardiovasc Surg       Date:  2011-06       Impact factor: 5.209

8.  Temporal trends in the incidence and prognosis of aortic stenosis: a nationwide study of the Swedish population.

Authors:  Andreas Martinsson; Xinjun Li; Charlotte Andersson; Johan Nilsson; J Gustav Smith; Kristina Sundquist
Journal:  Circulation       Date:  2015-02-17       Impact factor: 29.690

9.  Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study.

Authors:  Gian M Novaro; Ronit Katz; Ronnier J Aviles; John S Gottdiener; Mary Cushman; Bruce M Psaty; Catherine M Otto; Brian P Griffin
Journal:  J Am Coll Cardiol       Date:  2007-10-29       Impact factor: 24.094

Review 10.  Multimorbidity in Older Adults with Aortic Stenosis.

Authors:  Brian R Lindman; Jay N Patel
Journal:  Clin Geriatr Med       Date:  2016-02-12       Impact factor: 3.076

View more
  12 in total

1.  Predicting outcomes in patients with aortic stenosis using machine learning: the Aortic Stenosis Risk (ASteRisk) score.

Authors:  Mayooran Namasivayam; Paul D Myers; John V Guttag; Romain Capoulade; Philippe Pibarot; Michael H Picard; Judy Hung; Collin M Stultz
Journal:  Open Heart       Date:  2022-05

2.  Associations between aortic regurgitation severity and risk of incident myocardial infarction and stroke among patients with degenerative aortic valve disease: insights from a large Chinese population-based cohort study.

Authors:  Guangxiao Li; Tan Li; Yanli Chen; Xiaofan Guo; Zhao Li; Ying Zhou; Hongmei Yang; Shasha Yu; Guozhe Sun; Liqiang Zheng; Yingxian Sun
Journal:  BMJ Open       Date:  2021-08-26       Impact factor: 3.006

3.  Transvalvular Flow Rate Determines Prognostic Value of Aortic Valve Area in Aortic Stenosis.

Authors:  Mayooran Namasivayam; Wei He; Timothy W Churchill; Romain Capoulade; Shiying Liu; Hang Lee; Jacqueline S Danik; Michael H Picard; Philippe Pibarot; Robert A Levine; Judy Hung
Journal:  J Am Coll Cardiol       Date:  2020-04-21       Impact factor: 24.094

4.  Rapid progression of aortic stenosis after initiation of teriparatide treatment: a case report.

Authors:  Arie Solomon; Shlomo Birkenfeld
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-07-07

Review 5.  Genetic and Developmental Contributors to Aortic Stenosis.

Authors:  Punashi Dutta; Jeanne F James; Hail Kazik; Joy Lincoln
Journal:  Circ Res       Date:  2021-04-29       Impact factor: 17.367

6.  MG 53 Protein Protects Aortic Valve Interstitial Cells From Membrane Injury and Fibrocalcific Remodeling.

Authors:  T M Ayodele Adesanya; Melanie Russell; Ki Ho Park; Xinyu Zhou; Matthew A Sermersheim; Kristyn Gumpper; Sara N Koenig; Tao Tan; Bryan A Whitson; Paul M L Janssen; Joy Lincoln; Hua Zhu; Jianjie Ma
Journal:  J Am Heart Assoc       Date:  2019-02-19       Impact factor: 5.501

7.  Prognostic value of Mini Nutritional Assessment-Short Form with aortic valve stenosis following transcatheter aortic valve implantation.

Authors:  Shunichi Doi; Kohei Ashikaga; Keisuke Kida; Mika Watanabe; Kihei Yoneyama; Norio Suzuki; Shingo Kuwata; Toshiki Kaihara; Masashi Koga; Kazuaki Okuyama; Ryo Kamijima; Yasuhiro Tanabe; Naoya Takeichi; Satoshi Watanabe; Masaki Izumo; Yuki Ishibashi; Yoshihiro J Akashi
Journal:  ESC Heart Fail       Date:  2020-09-10

8.  Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk.

Authors:  Ahmed A Kolkailah; Rami Doukky; Marc P Pelletier; Annabelle S Volgman; Tsuyoshi Kaneko; Ashraf F Nabhan
Journal:  Cochrane Database Syst Rev       Date:  2019-12-20

9.  Durability of bioprosthetic aortic valves in patients under the age of 60 years - rationale and design of the international INDURE registry.

Authors:  Bart Meuris; Michael A Borger; Thierry Bourguignon; Matthias Siepe; Martin Grabenwöger; Günther Laufer; Konrad Binder; Gianluca Polvani; Pierluigi Stefano; Enrico Coscioni; Wouter van Leeuwen; Philippe Demers; Francois Dagenais; Sergio Canovas; Alexis Theron; Thierry Langanay; Jean-Christian Roussel; Olaf Wendler; Giovanni Mariscalco; Renzo Pessotto; Beate Botta; Peter Bramlage; Ruggero de Paulis
Journal:  J Cardiothorac Surg       Date:  2020-05-27       Impact factor: 1.637

10.  3D printed patient-specific aortic root models with internal sensors for minimally invasive applications.

Authors:  Ghazaleh Haghiashtiani; Kaiyan Qiu; Jorge D Zhingre Sanchez; Zachary J Fuenning; Priya Nair; Sarah E Ahlberg; Paul A Iaizzo; Michael C McAlpine
Journal:  Sci Adv       Date:  2020-08-28       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.